Takeda Pharmaceutical

The FDA has approved Mimrylo (active ingredient rusfertid) from Takeda for the treatment of erythrocytosis in adults with polycythaemia vera. The decision is based on the phase‑III VERIFY study with 293 patients, in which 76.9% of treated patients showed a clinical response between weeks 20 and 32 and reduced hematocrit levels, fewer phlebotomies, and relief of fatigue were documented. Mimrylo is administered once weekly subcutaneously; common adverse events were injection‑site reactions (56%) and anemia (16%). Takeda holds the exclusive global development and commercialization rights and does not expect an impact on consolidated guidance for the fiscal year. » Plus sur de.investing.com

The FDA has approved Orzeyful (Oveporexton) from Takeda for the treatment of narcolepsy type 1 in adults. Orzeyful is an oral orexin receptor-2 agonist; the approval is based on two phase‑III studies (FirstLight, RadiantLight) showing significant improvements in daytime sleepiness, cataplexy and quality of life. Common adverse effects were insomnia, increased urination and increased salivation; the drug is contraindicated with strong CYP3A inhibitors. The DEA is still reviewing the controlled-substance scheduling; once that process is complete, dispensing will be via specialty pharmacies. Takeda does not expect a material impact on consolidated financial guidance for the fiscal year ending 31.03.2027. » Plus sur de.investing.com

Takeda presented strong clinical results from two phase-3 studies in plaque psoriasis: about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin by week 16 versus 7% and 13% on placebo. In palmoplantar psoriasis roughly 70% of zasocitinib patients achieved clear or almost clear skin versus 22% and 10% on placebo; responses were maintained through week 24. Zasocitinib also showed better scalp results than apremilast (77%/74% vs. 42%/30%) and improved the Nail Psoriasis Severity Index. Common adverse events through week 24 included upper respiratory tract infections, nasopharyngitis and acne, with no new safety signals. Takeda plans regulatory filings for plaque psoriasis in this fiscal year and is conducting further studies in psoriatic arthritis, Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa. » Plus sur de.investing.com